Presentations

Below is a list of additional conferences and events at which Calviri has previously presented.

2022
Calviri Is Positioned to Become an Integral Part of Cancer Care
Calviri

2020
RNA Frameshift Errors Provide New Vaccine Product Opportunities Against Cancer
World Vaccine Congress

Ending Death from Cancer - Calviri presents investment opportunity
JP Morgan

2019
Going to the Dogs – How the Largest Canine Clinical Trial in History May Lead to New Hope for Humans
Arizona Bioindustry Association

Shifting the paradigm in diagnosing and treating cancer
Midwestern University

RNA generated frameshift neoantigens in tumors are useful in diagnosis and vaccination
Molecular Med Tri-Con

Using a blood-based 400K frameshift peptide array to develop cancer type-specific vaccinations
Molecular Med Tri-Con

A new source of neoantigens and a platform for their discovery
PepTalk

2018
Cancer type specific FAST vaccines based on frameshift neoantigens
Molecular Med Tri-Con

Tapping a new source of neoantigens: applications in therapy and diagnostics
Immune Oncology Summit

A new blood based approach to early diagnosis of cancer
American College of Veterinary Internal Medicine

Calviri’s Technology Enables a Universal Preventative Vaccine
Golden Retriever Club of America

Inventions to effectively eradicate cancer
United States Patent and Trademark Office

Shifting the paradigm in diagnosing and treating cancer
European NeoAG Summit

2017
An alternative source of neoantigens offers new approaches to personal and general vaccines
Golden Retriever Club of America